Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Neuro-Oncology

• Publication date

  2010-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11060-009-0067-2PMID 19960228
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.

  2009cited by this paper
• Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

  2008cited by this paper
• Variation of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma

  2008cited by this paper
• Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies

  2007cited by this paper
• Schedule-Dependent Interaction between the Proteosome Inhibitor Bortezomib and the EGFR-TK Inhibitor Erlotinib in Human Non-small Cell Lung Cancer Cell Lines

  2007cited by this paper
• Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

  2007cited by this paper
• Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

  2007cited by this paper
• Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non–Small Cell Lung Cancer Cells

  2007cited by this paper
• Amplification of the epidermal‐growth‐factor‐receptor gene correlates with different growth behaviour in human glioblastoma

  2007cited by this paper
• Pulmonary Fibrosis in a Patient Treated with Erlotinib

  2006cited by this paper
• Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.

  2006cited by this paper
• Treatment of glioblastoma multiforme: a new standard.

  2006cited by this paper
• Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.

  2006cited by this paper
• Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation★

  2006cited by this paper
• Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.

  2005cited by this paper
• TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

  2005cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005influential reference
• Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel

  2005cited by this paper
• Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

  2004cited by this paper
• Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines.

  2004cited by this paper
• Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme

  2004cited by this paper
• Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

  2004cited by this paper
• Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide

  2004cited by this paper
• Phase II trial of gefitinib in recurrent glioblastoma.

  2004cited by this paper
• Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent Glioblastoma Multiforme: Interim results.

  2004cited by this paper
• Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.

  2004cited by this paper
• Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer.

  2004cited by this paper
• EGFR but not PDGFR-beta expression correlates to the antiproliferative effect of growth factor withdrawal in glioblastoma multiforme cell lines.

  2003cited by this paper
• Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.

  2003cited by this paper
• Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394.

  2003cited by this paper
• Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa').

  2003cited by this paper
• Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.

  2002cited by this paper
• The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.

  2002cited by this paper
• EGFR overexpression and radiation response in glioblastoma multiforme.

  2001cited by this paper
• p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells.

  2001cited by this paper
• The autocrine loop of TGF-α/EGFR and brain tumors

  1997cited by this paper
• The autocrine loop of TGF-alpha/EGFR and brain tumors.

  1997cited by this paper
• Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

  1993cited by this paper
• Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro.

  1990cited by this paper
• Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin

  1985cited by this paper

• Redundancy in Growth Factor Receptor Signaling in Adult Astrocytoma Resistance to Small-Molecule Tyrosine Kinase Inhibitors

  2026cites this paper
• PDGFRA in paediatric high-grade glioma – target or distraction?

  2025cites this paper
• The role of biological macromolecules in the regulation of angiogenesis in glioblastoma: Focus on vascular growth factors, integrins, and extracellular matrix proteins.

  2025cites this paper
• Cut the fat: targeting cholesterol and lipid metabolism in glioblastoma

  2025cites this paper
• The safety and efficacy of tyrosine kinase inhibitors against EGFR in patients with glioma; A systematic review, meta-analysis, and sub-group analysis on glioblastoma.

  2025cites this paper
• Structure-based drug design of small molecule AKT1 inhibitors to treat glioma

  2025cites this paper
• Development of investigational radiotherapeutics for the diagnosis and treatment of glioma

  2025cites this paper
• Application of EGFR-TKIs in brain tumors, a breakthrough in future?

  2025cites this paper
• Revolutionizing Glioblastoma Treatment: A Comprehensive Overview of Modern Therapeutic Approaches

  2024cites this paper
• Challenges and advances in glioblastoma targeted therapy: the promise of drug repurposing and biomarker exploration

  2024cites this paper
• Glioblastoma Therapy: Past, Present and Future

  2024cites this paper
• The Role of Reirradiation in Childhood Progressive Diffuse Intrinsic Pontine Glioma (DIPG): An Ongoing Challenge beyond Radiobiology

  2023cites this paper
• Understanding Glioblastoma Signaling, Heterogeneity, Invasiveness, and Drug Delivery Barriers

  2023cites this paper
• Targeted therapies in patients with newly diagnosed glioblastoma—A systematic meta‐analysis of randomized clinical trials

  2023cites this paper
• Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma

  2022cites this paper
• Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review

  2022cites this paper
• Anoctamins and Calcium Signalling: An Obstacle to EGFR Targeted Therapy in Glioblastoma?

  2022cites this paper
• Therapeutic Options in Neuro-Oncology

  2022cites this paper
• A heat shock protein 90 inhibitor reduces oncoprotein expression and induces cell death in heterogeneous glioblastoma cells with EGFR, PDGFRA, CDK4, and NF1 aberrations.

  2021cites this paper
• Updated Insights on EGFR Signaling Pathways in Glioma

  2021cites this paper
• Bivalent Genes Targeting of Glioma Heterogeneity and Plasticity

  2021cites this paper
• Biology and Treatment of Glioblastoma : Future Direction of Basic Research

  2021cites this paper
• A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials

  2021cites this paper
• Investigational new drugs against glioblastoma

  2021cites this paper
• Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.

  2021cites this paper
• Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma

  2021influential citation
• Glioblastoma: a molecular genetic portrait and modern therapeutic strategies for drug treatment

  2021cites this paper
• Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme

  2021cites this paper
• Epigenetics of Glioblastoma Multiforme: From Molecular Mechanisms to Therapeutic Approaches.

  2020cites this paper
• Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02.

  2020cites this paper
• EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma

  2020cites this paper
• Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition

  2020cites this paper
• Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy

  2020cites this paper
• Discrete coiled coil rotamers form within the EGFRvIII juxtamembrane domain.

  2020cites this paper
• Small molecule tyrosine kinase inhibitors in glioblastoma

  2020cites this paper
• Receptor Tyrosine Kinases: Principles and Functions in Glioma Invasion.

  2020cites this paper
• Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade

  2020cites this paper
• Mechanisms of EGFR Resistance in Glioblastoma

  2020influential citation
• Phase I and Pharmacology Study of Ropidoxuridine (IPdR) as Prodrug for Iododeoxyuridine-Mediated Tumor Radiosensitization in Advanced GI Cancer Undergoing Radiation

  2019cites this paper
• High level EGFR amplification in a newly established glioblastoma cell line 170-MG-BA.

  2019cites this paper
• Modulation of Antioxidant Potential with Coenzyme Q10 Suppressed Invasion of Temozolomide-Resistant Rat Glioma In Vitro and In Vivo

  2019cites this paper
• EGFR Oncogenes Expressed In Glioblastoma Are Activated As Covalent Dimers And Paradoxically Stimulated By Erlotinib

  2019cites this paper
• Radiosensitizers in the temozolomide era for newly diagnosed glioblastoma.

  2019cites this paper
• Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography

  2019cites this paper
• Radiation Responses of 2D and 3D Glioblastoma Cells: A Novel, 3D-specific Radioprotective Role of VEGF/Akt Signaling through Functional Activation of NHEJ

  2019cites this paper
• TNFα inhibitor C87 sensitizes EGFRvIII transfected glioblastoma cells to gefitinib by a concurrent blockade of TNFα signaling

  2019cites this paper
• Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells

  2018cites this paper
• Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response

  2018cites this paper
• EGF/EGFR upregulates and cooperates with Netrin-4 to protect glioblastoma cells from DNA damage-induced senescence

  2018cites this paper
• A biobank of patient-derived pediatric brain tumor models

  2018cites this paper
• Late toxicity in long-term survivors from a phase 2 study of concurrent radiation therapy, temozolomide and valproic acid for newly diagnosed glioblastoma.

  2018cites this paper
• Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial

  2018cites this paper
• Rôle de l'intégrine bêta 8 dans le maintien de l'état souche et la radiorésistance des cellules souches de glioblastomes : vers une nouvelle thérapie ciblée

  2018cites this paper
• Oligosaccharyltransferase Inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity

  2018cites this paper
• Dacomitinib: an investigational drug for the treatment of glioblastoma

  2018cites this paper
• Role of Radiosensitizers in Radiation Treatment of Gliomas.

  2018cites this paper
• Potential Epigenetic-Based Therapeutic Targets for Glioma

  2018cites this paper
• A TNF–JNK–Axl–ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma

  2017cites this paper
• Glioblastoma targeted therapy: updated approaches from recent biological insights

  2017cites this paper
• Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma

  2017cites this paper
• Advances in Biology and Treatment of Glioblastoma

  2017cites this paper
• Exploiting Genetic Vulnerabilities to Overcome Treatment Resistance in Adult Gliomas

  2017cites this paper
• Stem Cell-Based Approaches for Treatment of Glioblastoma

  2017cites this paper
• Technology Medicine Open Access book

  2017cites this paper
• Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study

  2017cites this paper
• Chapter 7 – Erlotinib

  2017cites this paper
• EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise

  2017cites this paper
• Recent Advances for Targeted Therapies in Glioblastoma

  2017cites this paper
• Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients.

  2017cites this paper
• DRES-06. PRIMARY RESISTANCE TO EGFR INHIBITION IN GLIOBLASTOMA IS MEDIATED BY A TNF-JNK-Axl-ERK SIGNALING AXIS

  2017cites this paper
• Time-sequenced drug delivery approaches towards effective chemotherapeutic treatment of glioma

  2017cites this paper
• Microglia-glioma cross-talk: a two way approach to new strategies against glioma.

  2017cites this paper
• Targeting Aberrant Signaling Pathways

  2017cites this paper
• Molecular and Microenvironmental Determinants of Glioma Stem-Like Cell Survival and Invasion

  2017cites this paper
• Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study

  2017cites this paper
• Recent Advances in Targeted Therapy for Glioma.

  2017cites this paper
• The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma

  2017cites this paper
• Simultaneous Interference with HER1/EGFR and RAC1 Signaling Drives Cytostasis and Suppression of Survivin in Human Glioma Cells in Vitro

  2017cites this paper
• The challenges associated with molecular targeted therapies for glioblastoma

  2016cites this paper
• Updates in Genetic Molecular Targeted Therapy for Glioblastoma

  2016cites this paper
• Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis

  2016cites this paper
• Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma

  2016cites this paper
• PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

  2016cites this paper
• Tumor Microenvironment, Hypoxia, and Stem Cell-Related Radiation Resistance

  2016cites this paper
• Delivery And Efficacy Of CDK4/6 Inhibitors In The Treatment Of Brain Tumors

  2016cites this paper
• Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma.

  2016cites this paper
• Following the journey of seven patients with recurrent high grade glioma through hypo-fractionated salvage radiation therapy and beyond

  2016cites this paper
• Chapter 24 – Lessons Learned: Clinical Trials and Other Interventions for Glioblastoma

  2016cites this paper
• Sensitivity of GBM cells to cAMP agonist-mediated apoptosis correlates with CD44 expression and agonist resistance with MAPK signaling

  2016cites this paper
• Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models.

  2016influential citation
• The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity

  2016cites this paper
• Activation of AMP-activated kinase modulates sensitivity of glioma cells against epidermal growth factor receptor inhibition.

  2016cites this paper
• Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide

  2016cites this paper
• Radiobiological Hints from Clinical Studies

  2016cites this paper
• Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib

  2016cites this paper
• Small-Molecule Inhibitors in Glioblastoma: Key Pathways and Resistance Mechanisms

  2016cites this paper
• Bedeutung der EGFRvIII-Expression für die Radio- und Chemosensitivität von humanen Glioblastomzellen

  2015cites this paper
• Contemporary murine models in preclinical astrocytoma drug development.

  2015cites this paper
• A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients

  2015cites this paper
• Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review)

  2015cites this paper